Advanced Search


Study ID Status Title Patient Level Data
116266 Terminated A Three-Part Phase I, Open-Label, Single Ascending Dose, and A Single-Blind, Placebo-Controlled, Repeat Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Relative Bioavailability of Intravenous and Oral GSK1322322 in Healthy Volunteers and Healthy Male Japanese Subjects Study Listed on
116318 Completed Plan for Re-Evaluation of Sudden Unexplained Death in Epilepsy (SUDEP) Occurring in the Lamotrigine Clinical Development Program
116344 Completed PGx471: Combined pharmacogenetic analysis of IL28B genotypes in TPL108390 and TPL103922
116371 Completed A Phase 1, Open-Label, Crossover Study to Demonstrate the Bioequivalence of RYTHMOL SR® (propafenone hydrochloride) Manufactured at Two Different Sites Study Listed on
116402 Completed A multi-national, randomized, double-blind, placebo-controlled, 3-period crossover study with GSK 573719 as monotherapy in adult subjects with asthma Study Listed on
116416 Completed Single and Repeat Dose Pharmacokinetic Study of GSK1605786 in Healthy Chinese Subjects Study Listed on
116477 Completed Proof of Mechanism Study to Assess the Potential of GSK239512 to Remyelinate Lesions in Subjects with Relapsing Remitting Multiple Sclerosis Study Listed on
116490 Completed REMS Prescriber and Pharmacist Understanding of the Risk of Urinary Retention with POTIGA™
116524 Completed A randomized, double blind, single-dose, three-period, crossover study to investigate pharmacokinetic, safety and tolerability of Fluticasone Furoate with Umeclidinium when administered in combination and as monotherapies in adult healthy volunteer subjects Study Listed on
116554 Completed Incident Type II Diabetes Mellitus Among Patients Exposed to the Combination of Pravastatin and Paroxetine
116592 Completed A randomized, double-blind, placebo-controlled cross-over study to determine the bronchodilator effect of a single dose of fluticasone furoate (FF)/ vilanterol (VI) 100/25 mcg combination administered in the morning in adult patients with asthma Study Listed on
116595 Completed A Single Dose, Open Label, Randomized, Balanced, Crossover Study to Assess the Relative Bioavailability of ThreeFormulations and Food Effect on GSK1322322 in Healthy Subjects Study Listed on
116601 Completed A Randomised, Double-Blind, Placebo-Controlled, Cross-Over, Single-Centre Study to Investigate the Acute Lung Deflation Effects of Fluticasone Furoate/Vilanterol Inhalation Powder 100/25mcg Once Daily on Cardiac Biventricular Function and Arterial Stiffness in Adults with Chronic Obstructive Pulmonary Disease (COPD) Study Listed on
116602 Completed Risk of solid organ transplant rejection following vaccination with Pandemrix™ in the United Kingdom
116628 Completed A Single Center Phase 1 Double Blind Study to Evaluate the Effect of Losmapimod on Cardiac Conduction as Compared to Placebo and Moxifloxacin in Healthy Adult Subjects Study Listed on
116664 Completed Immunogenicity and safety study of GSK Biologicals’ Trivalent Split Virion Influenza Vaccine (GSK1536489A) Fluviral® (2012/2013 Season) in adults aged 18 years and older Study Listed on
116679 Completed A multi-centre, randomised, double-blind, placebo-controlled, dose ranging study to evaluate the safety and efficacy of GSK2586184 in patients with chronic plaque psoriasis Study Listed on
116681 Completed A Phase I, Randomized, Single-Blind, Three-Period Cross-Over, Placebo-Controlled, Single Oral Dose, Dose-Escalation (Part 1), Fixed Sequence, and Repeat Dose (Part 2) Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of losmapimod in Healthy Japanese Subjects. Study Listed on
116689 Completed An integrated review to evaluate dose response of umeclidinium (GSK573719) administered once or twice daily in Subjects with COPD
116698 Completed A Single-Blind, Randomized, Placebo-Controlled Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single, Oral Escalating Doses of GSK2647544 in Healthy Volunteers
116706 Active, Not Recruiting Pooled analysis of the assessment of the association of lung function improvements on COPD related exacerbations and other endpoints
116715 Completed A single-center, randomized, blinded, placebo-controlled two-part study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the Selective Androgen Receptor Modulator (SARM), GSK2849466, in single and repeat doses, with and without food, in healthy male subjects Study Listed on
116747 Completed PGx6202: Genetic Evaluation of Efficacy and Safety Endpoints in Patients with Ovarian Cancer in VEG110655/VEG114012
116753 Completed A randomized, double-blind, placebo-controlled, crossover study to evaluate the influence of the A118G polymorphism in the mu opioid receptor gene (OPRM1) on effects of GSK1521498 and naltrexone on physiological and behavioural markers of brain function in healthy social drinkers Study Listed on
116760 Completed Safety and immunogenicity study of GSK Biologicals’ Herpes Zoster subunit (HZ/su) vaccine GSK1437173A when administered subcutaneously versus intramuscularly in adults aged 50 years or older Study Listed on



For more information on this register please email

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party. is a database that provides summary protocol information for ongoing clinical trials. is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.